- Home
- BST vs CDNA Comparison
BST vs CDNA Comparison
Compare BST & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BST | CDNA |
|---|---|---|
| Founded | 2014 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 2014 | 2007 |
Fundamental Metrics
Financial Performance| Metric | BST | CDNA |
|---|---|---|
| Price | $49.70 | $48.21 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | 84.0K | ★ 1.1M |
| Earning Date | 01-01-0001 | 04-28-2026 |
| Dividend Yield | ★ 10.06% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.13 |
| Revenue | N/A | ★ $48,324,000.00 |
| Revenue This Year | N/A | $16.01 |
| Revenue Next Year | N/A | $11.31 |
| P/E Ratio | ★ N/A | $22.06 |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $34.87 | $12.37 |
| 52 Week High | $51.30 | $49.76 |
Technical Indicators
Market Signals| Indicator | BST | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 59.52 | 71.19 |
| Support Level | $44.24 | $16.20 |
| Resistance Level | $50.80 | $49.76 |
| Average True Range (ATR) | 0.78 | 1.85 |
| MACD | 0.09 | -0.39 |
| Stochastic Oscillator | 73.96 | 93.01 |
Price Performance
Historical ComparisonAbout BST BlackRock Science and Technology Trust of Beneficial Interest
BlackRock Science and Technology Trust is a closed-end management investment company. Its investment objectives are to provide total return and income through long-term capital appreciation.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.